Literature DB >> 24836421

The inflammatory sequelae of aortic balloon occlusion in hemorrhagic shock.

Jonathan J Morrison1, James D Ross2, Nickolay P Markov3, Daniel J Scott4, Jerry R Spencer2, Todd E Rasmussen5.   

Abstract

BACKGROUND: Resuscitative endovascular balloon occlusion of the aorta (REBOA) is a hemorrhage control and resuscitative adjunct that has been demonstrated to improve central perfusion during hemorrhagic shock. The aim of this study was to characterize the systemic inflammatory response associated and cardiopulmonary sequelae with 30, 60, and 90 min of balloon occlusion and shock on the release of interleukin 6 (IL-6) and tumor necrosis factor alpha.
MATERIALS AND METHODS: Anesthetized female Yorkshire swine (Sus scrofa, weight 70-90 kg) underwent a 35% blood volume-controlled hemorrhage followed by thoracic aortic balloon occlusion of 30 (30-REBOA, n = 6), 60 (60-REBOA, n = 8), and 90 min (90-REBOA, n = 6). This was followed by resuscitation with whole blood and crystalloid over 6 h. Animals then underwent 48 h of critical care with sedation, fluid, and vasopressor support.
RESULTS: All animals were successfully induced into hemorrhagic shock without mortality. All groups responded to aortic occlusion with a rise in blood pressure above baseline values. IL-6, as measured (picogram per milliliter) at 8 h, was significantly elevated from baseline values in the 60-REBOA and 90-REBOA groups: 289 ± 258 versus 10 ± 5; P = 0.018 and 630 ± 348; P = 0.007, respectively. There was a trend toward greater vasopressor use (P = 0.183) and increased incidence of acute respiratory distress syndrome (P = 0.052) across the groups.
CONCLUSIONS: REBOA is a useful adjunct in supporting central perfusion during hemorrhagic shock; however, increasing occlusion time and shock results in a greater IL-6 release. Clinicians must anticipate inflammation-mediated organ failure in post-REBOA use patients. Published by Elsevier Inc.

Entities:  

Keywords:  Hemorrhagic shock; Noncompressible torso hemorrhage; REBOA; Resuscitation; Resuscitative endovascular balloon occlusion of the aorta

Mesh:

Substances:

Year:  2014        PMID: 24836421     DOI: 10.1016/j.jss.2014.04.012

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  21 in total

1.  Resuscitative endovascular balloon occlusion of the aorta: what is the optimum occlusion time in an ovine model of hemorrhagic shock?

Authors:  V A Reva; Y Matsumura; T Hörer; D A Sveklov; A V Denisov; S Y Telickiy; A B Seleznev; E R Bozhedomova; J Matsumoto; I M Samokhvalov; J J Morrison
Journal:  Eur J Trauma Emerg Surg       Date:  2016-10-13       Impact factor: 3.693

2.  Complete and Partial Aortic Occlusion for the Treatment of Hemorrhagic Shock in Swine.

Authors:  Aaron M Williams; Umar F Bhatti; Isabel S Dennahy; Kiril Chtraklin; Panpan Chang; Nathan J Graham; Basil M Baccouche; Shalini Roy; Mohammed Harajli; Jing Zhou; Vahagn C Nikolian; Qiufang Deng; Yuzi Tian; Baoling Liu; Yongqing Li; Gregory L Hays; Julia L Hays; Hasan B Alam
Journal:  J Vis Exp       Date:  2018-08-24       Impact factor: 1.355

3.  The effect of thoracic aortic balloon occlusion during hemorrhagic shock on spinal cord and visceral organ damage.

Authors:  Undefined DemiropoulosF; K Papazoglou; D Miliaras
Journal:  Hippokratia       Date:  2016 Jul-Sep       Impact factor: 0.471

4.  Arterial waveform morphomics during hemorrhagic shock.

Authors:  Philip J Wasicek; William A Teeter; Shiming Yang; Peter Hu; William B Gamble; Samuel M Galvagno; Melanie R Hoehn; Thomas M Scalea; Jonathan J Morrison
Journal:  Eur J Trauma Emerg Surg       Date:  2019-04-23       Impact factor: 3.693

Review 5.  Pelvic trauma: WSES classification and guidelines.

Authors:  Federico Coccolini; Philip F Stahel; Giulia Montori; Walter Biffl; Tal M Horer; Fausto Catena; Yoram Kluger; Ernest E Moore; Andrew B Peitzman; Rao Ivatury; Raul Coimbra; Gustavo Pereira Fraga; Bruno Pereira; Sandro Rizoli; Andrew Kirkpatrick; Ari Leppaniemi; Roberto Manfredi; Stefano Magnone; Osvaldo Chiara; Leonardo Solaini; Marco Ceresoli; Niccolò Allievi; Catherine Arvieux; George Velmahos; Zsolt Balogh; Noel Naidoo; Dieter Weber; Fikri Abu-Zidan; Massimo Sartelli; Luca Ansaloni
Journal:  World J Emerg Surg       Date:  2017-01-18       Impact factor: 5.469

6.  Fluoroscopy-free Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) for controlling life threatening postpartum hemorrhage.

Authors:  Knut Haakon Stensaeth; Edmund Sovik; Ingrid Natasha Ylva Haig; Erna Skomedal; Arve Jorgensen
Journal:  PLoS One       Date:  2017-03-29       Impact factor: 3.240

Review 7.  A systematic review and meta-analysis of the use of resuscitative endovascular balloon occlusion of the aorta in the management of major exsanguination.

Authors:  B L S Borger van der Burg; Thijs T C F van Dongen; J J Morrison; P P A Hedeman Joosten; J J DuBose; T M Hörer; R Hoencamp
Journal:  Eur J Trauma Emerg Surg       Date:  2018-05-21       Impact factor: 3.693

8.  Partial resuscitative balloon occlusion of the aorta (P-REBOA): Clinical technique and rationale.

Authors:  M Austin Johnson; Lucas P Neff; Timothy K Williams; Joseph J DuBose
Journal:  J Trauma Acute Care Surg       Date:  2016-11       Impact factor: 3.313

9.  Use of bilobed partial resuscitative endovascular balloon occlusion of the aorta is logistically superior in prolonged management of a highly lethal aortic injury.

Authors:  Jevgenia Zilberman-Rudenko; Brandon Behrens; Belinda McCully; Elizabeth N Dewey; Sawyer G Smith; James M Murphy; Andrew Goodman; Samantha J Underwood; Elizabeth A Rick; Brianne M Madtson; Michelle E Thompson; Jacob J Glaser; John B Holcomb; Martin A Schreiber
Journal:  J Trauma Acute Care Surg       Date:  2020-09       Impact factor: 3.697

Review 10.  New perspectives of volemic resuscitation in polytrauma patients: a review.

Authors:  Ovidiu Horea Bedreag; Marius Papurica; Alexandru Florin Rogobete; Mirela Sarandan; Carmen Alina Cradigati; Corina Vernic; Corina Maria Dumbuleu; Radu Nartita; Dorel Sandesc
Journal:  Burns Trauma       Date:  2016-02-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.